News

News

Biogen share price soars as US accepts drug for Alzheimer’s

09 Jun 2021

 

 The stock gained as much as 64% shortly after the news of the clearance. The Food and Drug Administration (FDA) granted the antibody therapy accelerated approval.

The approval is the first clearance of an Alzheimer’s therapy by the FDA since 2003, and one of the agency’s most consequential decisions in years.

[BACK TO NEWS]